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Background.The oxygen cost (O
2
cost) of walking is elevated in persons with MS, particularly as a function of increasing disability
status. Objective. The current study examined symptomatic (i.e., fatigue, pain, anxiety, and depression) and gait (i.e., velocity,
cadence, and step length) variables that might explain why disability status is associated with O
2
cost of walking in persons
with MS.Materials and Methods. 82 participants completed the Patient-Determined Disease Steps, Fatigue Severity Scale, McGill
Pain Questionnaire, and Hospital Anxiety and Depression Scale and undertook 2 trials of walking on a GAITRite electronic
walkway. Participants then completed a six-minute walk test with concurrent assessment of expired gases for quantifying oxygen
consumption and O
2
cost of walking. Results. Disability (𝑟 = 0.55) as well as fatigue (𝑟 = 0.22), gait velocity (𝑟 = −0.62), cadence
(𝑟 = −0.73), and step length (𝑟 = −0.53) were associated with the O
2
cost of walking. Cadence (𝛽 = −0.67), but not step length
(𝛽 = −0.14) or fatigue (𝛽 = −0.10), explained the association between disability and the O
2
cost of walking. Conclusions. These
results highlight cadence as a target of rehabilitation for increasing metabolic efficiency during walking among those with MS,
particularly as a function of worsening disability.
1. Introduction
The impairment of walking is a hallmark feature of neurologi-
cal diseases such asmultiple sclerosis (MS) [1, 2]. For example,
there is evidence that persons with MS expend more energy
than controls without MS when performing comparable
walking assessments (e.g., 6 minutes of walking at 3mph)
[3, 4]. This increase in energy expenditure can be expressed
in terms of the oxygen cost (O
2
cost) of walking. The O
2
cost of walking is defined as the amount of oxygen consumed
per kilogram of body weight over a distance traveled (i.e.,
mL/kg/m). Conceptually, the O
2
cost of walking reflects
the total energy required for over-ground ambulation and
can change as a function of reduced distance traveled for
the same amount of energy expended or as a function of
increased energy expenditure for traveling the same distance.
The O
2
cost of walking, therefore, represents a physiological
marker of walking impairment that reflects the contribution
of pathologic gait abnormalities and possibly symptomatic
manifestations caused by neurological disability [5].
Of note, there is preliminary evidence that the O
2
cost of
walking is associated with disability status and perhaps other
disease-related consequences in persons with mild MS. For
example, one study reported that those with worse disability
demonstrated a higher O
2
cost of walking during 6-minute
bouts of walking on a treadmill or over-ground in samples of
18 and 24 persons with MS, respectively [6]. Another study
reported that the O
2
cost of walking on a treadmill was asso-
ciated with spatiotemporal parameters of gait (e.g., velocity,
stride length, and double limb support) and symptomatic
fatigue in 44 persons with MS who had minimal disability
[7]; other research has reported a nonsignificant correlation
between the O
2
cost of walking and symptomatic fatigue
[8]. One limitation of those previous studies is the inclusion
of persons with relatively mild MS-related disability; this
limits our understanding of the association between disability
and O
2
cost of walking across a broader range of mobility
impairment in MS. There further is minimal research on
variables that explain the association between disability and
O
2
cost of walking; this limits our understanding of targets for
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possibly reducing the O
2
cost of walking across the mobility-
disability spectrum in MS.
The current study examined potential symptomatic (i.e.,
fatigue, pain, anxiety, and depression) and gait (i.e., velocity,
cadence, and step length) variables as factors that might
explain the association between disability status and the O
2
cost of walking in a relatively large sample of 82 persons with
MSwho had a broad range of disability.We expected that dis-
ability status would correlate with O
2
cost of walking and that
the association would be accounted for by gait parameters
and symptomatic variables. Such an examination is important
for (a) further understanding the O
2
cost of walking as a
function of neurological disability status in persons with MS
and (b) identifying targets of interventions for reducing the
O
2
cost of walking in this population.
2. Materials and Methods
2.1. Participants. The data were secondary outcomes from
the baseline testing session of a behavioral intervention for
increasing physical activity in persons with MS [9]. Partic-
ipants were contacted (a) by mail through a flyer that was
sent to patients in North American Research Committee
on Multiple Sclerosis (NARCOMS) registry or (b) by e-mail
through a flyer that was sent to participants in a database
from previous studies conducted in our laboratory over the
past five years. There were 511 participants who initially
expressed interest and who were contacted via phone by
the project coordinator. After explaining the study protocol,
the project coordinator undertook screening for inclusion
with 230 individuals who remained interested. The inclusion
criteria involved (a) having a definite diagnosis of MS (i.e.,
physician’s verification of MS diagnosis), (b) being relapse-
free for the past 30 days, (c) being able to walk with or
without an assistive device (i.e., cane, crutch, or walker) for
collection of O
2
cost of walking and gait outcomes, (d) being
between 18 and 64 years of age, (e) being willing and able to
travel to our laboratory to complete the walking assessments,
(f) participating in less than 3 days per week of physical
activity behavior, (g) having a low risk for contraindications
of physical activity based on no more than a single “yes”
response on the Physical Activity Readiness Questionnaire
(PAR-Q) [10], and (h) being able to provide a physician’s
approval for participation in the study. Of the 230 persons
who were screened, 106 did not meet inclusion criteria, with
the primary reasons being too physically active (𝑛 = 57) or
unwilling to travel to our laboratory (𝑛 = 23); 39 additional
persons did not provide physician’s approval; and 3 cancelled
the testing session due to scheduling conflicts. This resulted
in a final sample of 82 persons with MS who were enrolled in
this study.
2.2. Primary Measures
2.2.1. Oxygen Cost of Walking. Oxygen consumption (VO
2
)
was measured breath-by-breath using a commercially avail-
able portable metabolic unit (K4b2 Cosmed, Italy) during
a standard 6-minute walk (6MW) test that was performed




analyzers of the portable metabolic unit were
calibrated using known concentrations of gases, and the flow-
meter was calibrated using a 3 L syringe (Hans Rudolph,
Kansas City, MO). We measured VO
2
(mL/kg/min) as 30-
second averages for 1 minute both before the 6MW (i.e.,
resting VO
2
) and over the entire 6MW.We further measured
total distance traveled (m) using a measuring wheel (Stanley
MW50, New Briton, CT). We determined net steady-state
VO
2




values across the final 3 minutes of the 6MW (i.e., steady-
stateVO
2
;minutes 4–6) and (b) subtracting resting-stateVO
2
values for the 1 minute prior to the 6MW. The O
2
cost of
walking was then computed by dividing net steady-state VO
2
(mL/kg/min) bywalking speed during the 6MW(m/min) [5];
this resulted in O
2
cost of walking expressed as mL/kg/m.
2.2.2. Disability Status. The Patient Determined Disease
Steps (PDDS) scale [11] was included as a self-report measure
of disability status. The PDDS was developed as an inex-
pensive surrogate for the Expanded Disability Status Scale
(EDSS) [12] and contains a single item for measuring self-
reported neurological impairment on an ordinal scale, rang-
ing from 0 (normal) to 8 (bedridden).This scale has been val-
idated inMS based on a strong correlationwith a neurologist-
administered EDSS (𝜌 = 0.78) and comparable strong
correlations between the PDDS and EDSSwith othermarkers
of ambulatory status (e.g., Multiple Sclerosis Walking Scale-
12, T25FW, 6MW distance) [13].
2.2.3. Symptoms. Fatigue was measured with the 9-item
Fatigue Severity Scale (FSS) [14]. Pain was measured using
the 15-item, short form of the McGill Pain Questionnaire
(SF-MPQ) [15]. Symptoms of anxiety and depression were
measured using the Hospital Anxiety and Depression Scale
(HADS) [16]. These scales have all been included in previous
research involving persons with MS [17–20].
2.2.4. Gait Parameters. Participants completed two trials of
walking on a 16-foot GAITRite (CIR Systems, Inc.) electronic
walkway at a self-selected pace for measuring gait outcomes.
We recorded velocity (cm/sec), cadence (steps/min), and step
length (cm) among other variables provided by theGAITRite.
These variables were selected based on previously reported
differences between persons with MS and healthy controls
[21] and associations with disability status [22] and 6MW
distance [23] in samples of persons withMS.We averaged the
recorded values per variable across both trials.
2.3. Protocol. The protocol was approved by a University
Institutional Review Board and all participants provided
written informed consent. The protocol included a single
session for collecting all data on the University of Illinois at
Urbana-Champaign campus. All participants initially com-
pleted a battery of questionnaires including a demographics
inventory, PDDS, FSS, SF-MPQ, and HADS. Participants
then completed two trials on the GAITRite, followed by
10 minutes of seated rest. Participants were fitted with the
portable metabolic system during the seated rest. Once wear-
ing the system and after ensuring normal, resting metabolic
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functioning, participants were given standardized instruc-
tions for undertaking the 6MW and then completed the
6MW test. All participants were remunerated $50 for com-
pleting the session.
2.4. Data Analysis. All data were analyzed in SPSS ver-
sion 21.0 (SPSS Inc., Chicago, IL). Descriptive statistics are
presented as means (standard deviations), unless otherwise
noted. We first examined the data for outliers using visual
inspection of scatter plots and distributions of data; persons
with data points that were 3.29 standard deviations above the
mean on any measure were considered extreme cases and
subsequently Winsorized [24]. Missing data were replaced
with the group mean [24]. We then performed bivariate
Pearson product-moment correlations (r) among disability
status, symptoms, gait variables, and the O
2
cost of walking.
Values for correlation coefficients of 0.1, 0.3, and 0.5 were
interpreted as small, moderate, and large, respectively [25].
We performed hierarchical linear regression with direct
entry to examine if symptomatic/gait variables explained
the association between disability status and the O
2
cost
of walking. This was undertaken by regressing the O
2
cost
of walking on disability status in Step 1 and then adding
symptomatic and gait variables that correlated with both
disability and O
2
cost of walking in Step 2. We compared the
𝛽-coefficient for disability status between Step 1 and Step 2
to examine if symptomatic and gait variables accounted for
the association between disability and O
2
cost of walking.We
further examined the 𝛽-coefficients for the symptomatic and
gait variables to identify the independent contributions for




3.1. Demographic and Clinical Characteristics. The sample
included 82 persons with a definite diagnosis of MS. The
samplewasmostly female (𝑛 = 63/82; 76.8%), with an average
age of 49.1 (SD = 9.0) years, height of 169.0 (SD = 8.5)
centimeters, and weight of 80.3 (SD = 21.7) kilograms. 64
participants reported having relapsing-remittingMS (78.0%),
and 18 reported having a progressive clinical course (22.0%).
The mean duration of MS was 11.9 (SD = 8.1) years, and the
median PDDS score was 3 (range = 0–6) indicatingmoderate
disability (i.e., the onset of gait impairment) with a range in
mobility disability between normal and bilateral support.
3.2. Symptomatic, Gait, and Oxygen Cost of Walking Char-
acteristics. Symptomatic and gait outcomes are reported in
Table 1. Collectively, the current sample demonstrated ele-
vated fatigue, pain, anxiety, and depression typical of per-
sons with MS [17–20]. The sample further had similar gait
characteristics compared with other samples of persons with
MS [26]. Average resting-state VO
2
was 3.7 (SD = 1.1)
mL/kg/min, and this is expected as one MET (i.e., one
metabolic equivalent; 3.5mL/kg/min) is generally considered
to be resting-state and our resting VO
2
value corresponds
with 1.1METs. Figure 1 depicts VO
2
in 30-second intervals
over the course of 6MW. This is indicative of steady-state
Table 1: Symptomatic and gait characteristics for 82 persons with
MS.





Gait velocity (cm/s) 98.32 (33.00)
Cadence (steps/min) 98.97 (19.95)
Step length (cm) 58.00 (13.05)
Note. FSS: Fatigue Severity Scale; SF-MPQ: Short-Form McGill Pain Ques-
tionnaire; HADS: Hospital Anxiety and Depression Scale. All data are




























Figure 1: Oxygen consumption over a six-minute walk test in






occurring at approximately 180 seconds into the 6MW;
the average steady-state VO
2
was 13.9 (SD = 3.8) mL/kg/min
and this would be considered moderate-intensity walking as
it approximated 4METS [27].Mean 6MWdistance was 418.8
(SD = 152.5) m, and average 6MW speed was 69.8 (SD =
25.4)m/min, resulting in an average net O
2
cost of walking
of 0.16 (SD = 0.07)mL/kg/m; this value is similar to O
2
costs
of walking reported in other samples of persons withMS (i.e.,
0.13–0.18mL/kg/m) [6–8].
3.3. Associations among Disability, Symptoms, Gait, and Oxy-
gen Cost ofWalking. Thecorrelations among variables for the
overall sample are provided in Table 2. Briefly, PDDS scores
were significantly associated with the O
2
cost of walking (𝑟 =
0.546, 𝑃 < 0.001) indicating that those with worse disability
had worse walking efficiency. Regarding symptoms, fatigue,
pain, and depression, but not anxiety, were significantly
associated with PDDS scores. However, among symptomatic
variables, only fatigue was associated with O
2
cost of walking
(𝑟 = 0.223); the scatter plot for this correlation is presented in
Figure 2. Regarding spatiotemporal gait parameters, velocity,
cadence, and step length were negatively associated with both
PDDS scores and the O
2
cost of walking, and the correlations
were large in magnitude (r’s between −0.528 and −0.730).
The scatter plots for these associations are further presented
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Table 2: Pearson product-moment correlations (𝑟) among oxygen cost ofwalking, Patient-DeterminedDisease Steps scores, and symptomatic
and gait variables in 82 persons with MS.
Variable 1 2 3 4 5 6 7 8 9
(1) O2 cost of walking —
(2) PDDS 0.546∗∗ —
(3) FSS 0.223∗ 0.539∗∗ —
(4) SF-MPQ 0.059 0.380∗∗ 0.515∗∗ —
(5) HADS-anxiety −0.051 0.069 0.320∗∗ 0.279∗ —
(6) HADS-depression 0.078 0.291∗∗ 0.475∗∗ 0.401∗∗ 0.413∗∗ —
(7) Gait velocity −0.620∗∗ −0.791∗∗ −0.457∗∗ −0.358∗∗ −0.082 −0.236∗ —
(8) Cadence −0.730∗∗ −0.684∗∗ −0.318∗∗ −0.234∗ −0.017 −0.141 0.845∗∗ —
(9) Step length −0.528∗∗ −0.719∗∗ −0.441∗∗ −0.363∗∗ −0.113 −0.229∗ 0.933∗∗ 0.626∗∗ —
Note.∗∗significance at 𝑝 < 0.01; ∗significance at 𝑝 < 0.05; PDDS: Patient-Determined Disease Steps; FSS: Fatigue Severity Scale; SF-MPQ: Short-FormMcGill

















































































Figure 2: Scatter plots of oxygen cost of walking (mL/kg/m) and (a) fatigue, (b) gait velocity (cm/s), (c) cadence (steps/min), and (d) step
length (cm) along with lines of best fit and 95% confidence intervals in 82 persons with multiple sclerosis.
in Figure 2. Collectively, this indicates that persons with MS
who had worse disability, fatigue, and gait (indexed by slower
gait, characterized by fewer and shorter steps) expendedmore
energy per meter walked.
3.4. Regression Analyses. The results for the hierarchical
linear regression analyses are in Table 3. We included fatigue
severity as the only symptomatic outcome in the regressions
because this was the sole symptomatic variable that was
significantly associated with both PDDS scores andO
2
cost of
walking. Disability status (𝐵 = 0.019, SE 𝐵 = 0.004, and
𝛽 = 0.518) explained a statistically significant (F (1, 79) =
28.959, 𝑝 < 0.001) portion of variance in the O
2
cost of walk-
ing (𝑅2 = 0.26) in Step 1.We included fatigue and gait velocity
only, as velocity was strongly correlated with cadence and
step length (i.e., cadence and step length are subcomponents
of gait velocity) in Step 2a of the model. The 𝛽-coefficient
for disability status became attenuated and nonsignificant
(𝛽 = 0.12, 𝑝 = 0.43) and gait velocity (𝛽 = −0.57), but
not fatigue (𝛽 = −0.10), explained a statistically significant
amount of variance in the O
2
cost of walking (Δ𝑅2 =
0.11). We were interested in the independent contributions
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Table 3: Summary of hierarchical linear regression analyses for
predicting oxygen-cost of walking in 82 persons with MS.
Variable 𝐵 SE 𝐵 𝛽
Step 1
PDDS 0.0188 0.0035 0.518∗
Step 2a
PDDS 0.0045 0.0056 0.123
FSS −0.0047 0.0048 −0.103
Gait velocity −0.0011 0.0003 −0.570∗
Step 2b
PDDS −0.0015 0.0045 −0.040
Cadence −0.0022 0.0004 −0.671∗
Step length −0.0007 0.0006 −0.137
Note. 𝑅2 = 0.259 for Step 1; Δ𝑅2 = 0.111 for Step 2a; Δ𝑅2 = 0.264 for Step
2b (𝑝 < 0.05, two-tailed test).
∗
𝑝 < 0.05 with one-tailed test.
of the subcomponents of gait velocity in Step 2b of the model
and included cadence and step length in place of velocity.
The𝛽-coefficient for disability status again became attenuated
and nonsignificant (𝛽 = −0.04, 𝑝 = 0.75), and cadence (𝛽 =
−0.67, 𝑝 < 0.001), but not step length (𝛽 = −0.14, 𝑝 = 0.24),
explained a statistically significant amount of variance in the
O
2
cost of walking (Δ𝑅2 = 0.26).
4. Discussion
This study examined symptoms and gait parameters as
variables that explain the association between disability status
with O
2
cost of walking in 82 persons with MS who had a
large range of mobility disability from ambulatory without
assistance through bilateral support. O
2
cost of walking was
associated with disability status such that those with worse
disability had a greater O
2
cost of walking. Fatigue, gait
velocity, cadence, and step length, but not pain, anxiety, and
depression, were associated with both disability status andO
2
cost of walking. Gait velocity, but not fatigue, explained the
association between disability status and O
2
cost of walking,
and we further identified cadence as the primary component
of gait velocity that explained the association. Collectively,
such results provide further evidence that worse disability
status is associated with higher O
2
cost of walking and
identify gait cadence as a target of rehabilitative interventions
for possibly improvingmetabolic efficiency duringwalking in
those with MS.
We have previously reported that the O
2
cost of treadmill
and over-ground walking is associated with disability status
in persons with MS, and that spatiotemporal parameters of
gait and fatigue are associated with the O
2
cost of treadmill
walking in persons withmildMS disability [6, 7].The current
study replicated and extended those findings using over-
ground walking in a substantially larger sample of persons
with MS who had a broader range of disability. The novel
aspect of this study was that we included symptomatic and
gait-related outcomes as potential mediators of the associ-
ation between disability status and the O
2
cost of walking
in persons with MS. The primary novel findings were that
fatigue and parameters of gait, but not other symptoms, were
associated with disability and the O
2
cost of walking and
that cadence, but not step length, explained the association
between disability status and O
2
cost of walking. This indi-
cates that cadence is the primary gait parameter that results
in the energetic penalty of walking imposed by disability in
MS.
To our knowledge, this study is the first to examine step
length and cadence as intermediate variables in the asso-
ciation between MS disability and the O
2
cost of walking.
Interestingly, stride length (i.e., the sum of two step lengths)
and cadence have been previously identified as partial medi-
ators of the association between MS disability and 6MW
distance [23]. The current results suggest that cadence, but
not step length, is a mediator of the association between MS
disability and the O
2
cost of walking during a 6MW. Such
results provide evidence for the general contributions of step
length and cadence towards 6MW distance and the specific
contribution of cadence towards the O
2
cost of walking.
The identification of cadence as a significant mediator of
the association between disability status and O
2
cost of
walking might be attributed to biomechanical inefficiencies
during walking. Slower cadence is associated with increases
in mediolateral displacement of the center of mass (i.e., poor
biomechanical efficiency) during walking in healthy adults
[28] and in persons with Down syndrome [29], presumably
resulting in energetic penalties during walking (i.e., increases
in the O
2
cost of walking) [5]. As such, the current results
support the development and implementation of interven-
tions for improving gait cadence tominimize possible biome-
chanically induced increases in the O
2
cost of walking that
are associated with worsening MS disability. This might be
accomplished through rhythmic auditory stimulation (RAS),
as one pilot study reported large improvements (d = 0.70) in
cadence following a one-week RAS intervention [30].
Pain, anxiety, and depression were not significantly asso-
ciated with the O
2
cost of walking. This was somewhat
expected as previous research has indicated that those vari-
ables were not associated with 6MW performance [31],
although this had not been established for O
2
cost of walking
in personswithMS.There has beenmixed evidence regarding
the association between the O
2
cost of walking and fatigue in
samples of persons with mild MS during treadmill [7] and
over-ground [8] walking tasks. Based on the current sample’s
broader range of disability, we did expect that fatigue would
account, in part, for disability-related increases in O
2
cost of
walking. Although fatigue was significantly associated with
both disability status and O
2
cost of walking, fatigue did not
explain the association between these variables; gait velocity,
and ultimately cadence, emerged as a significant mediator of
this association. This is reasonable as, presumably, persons
with worse MS disability walk slower and expend more
energy while walking, which might result in increased per-
ceptions of fatigue. As such, future research might consider
fatigue as a potential confound of the association between
disability status and O
2
cost of walking.
Another interesting aspect of the current study is that we
provide further validity evidence for the PDDS as a measure
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of mobility disability in MS. Indeed, the PDDS has previ-
ously been validated as a measure of disability status and
ambulatory status based on similarly strong associations with
the EDSS and MSWS-12, T25FW, and 6MW distance (𝜌’s
>0.63) [13]. The current study extends such validity evidence
based on strong associations among the PDDS and O
2
cost
of walking (𝑟 = 0.55), gait velocity (𝑟 = −0.79), cadence
(𝑟 = −0.68), and step length (𝑟 = −0.72). Collectively, this
strengthens the body of evidence supporting the PDDS
as a self-reported measure of disability status, particularly
mobility disability, in MS.
Strengths of the current study include the relatively large
sample size, inclusion of persons with a broad range of dis-
ability, and use of over-ground walking. This study is not
without limitations. One limitation includes the cross-sec-
tional research design, as it does not indicate causality
between disability, gait, and O
2
cost of walking. Neverthe-
less, we provide preliminary data necessary before investing
considerable time, effort, and resources into designing and
testing a rehabilitation program for improving cadence to
minimize the disability-related O
2
cost of walking in persons
with MS. The current study did not include a comparison
sample of healthy controls matched by age, sex, height, and
weight in order to better examine the specificity of cadence
as a predictor of the O
2
cost of walking in persons with MS.
Another limitation includes the use of the FSS as a self-report
measure of fatigue. The FSS does not discriminate between
physical and cognitive fatigue and might not be sufficient for
identifying specific domains of fatigue as separate predictors
of the O
2
cost of walking in persons with MS. As such, future
studies should consider the use of multidimensional scales
(e.g., Fatigue Scale for Motor and Cognitive Functions [32])
for examining physical and cognitive fatigue as separate pre-
dictors of the O
2
cost of walking in MS. One final limitation
of the current investigation is that the gait parameters were
not collected under the samewalking conditions as the 6MW.
This could have provided additional insight to examine
condition-related specificity of the associations among gait
parameters and O
2
cost of walking, though this was not an
aim of this study.
5. Conclusions
This cross-sectional study examined symptoms and gait
parameters as variables that account for the association
between disability and the O
2
cost of walking in 82 persons
with MS. To that end, the primary novel findings were
that fatigue and gait parameters, but not pain, anxiety, and
depression, were associated with disability status and O
2
cost
of walking. Hierarchical linear regression analyses indicated
that gait velocity, but not fatigue, explained variance in the
association between disability status and O
2
cost of walk-
ing. When decomposing velocity into its subcomponents
of cadence and step length, only cadence accounted for
the association between disability and O
2
cost of walking.
Collectively, these results suggest that slower cadence, per-
haps due to biomechanical inefficiencies, is responsible for
increases in O
2
cost of walking among persons with advanc-
ingMS disability.This highlights the importance of designing
and implementing interventions for minimizing gait-related
energetic penalties during walking among persons with MS.
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